WO2022079612 - METHOD AND COMPOUNDS FOR TREATING DIABETES AND ASSOCIATED METABOLIC DISEASES
National phase entry:
Publication Number
WO/2022/079612
Publication Date
21.04.2022
International Application No.
PCT/IB2021/059370
International Filing Date
12.10.2021
Title **
[English]
METHOD AND COMPOUNDS FOR TREATING DIABETES AND ASSOCIATED METABOLIC DISEASES
[French]
MÉTHODE ET COMPOSÉS POUR LE TRAITEMENT DU DIABÈTE ET DES MALADIES MÉTABOLIQUES ASSOCIÉES
Applicants **
BETAVIVE LTD.
5 Nahum Het Street
Topaz Building, Matam Center
31905 Haifa, IL
Inventors
PALTI, Yoram
51 Ruth Street
34404 Haifa, IL
ZURI, Dotan
2018300 Shekhanya, IL
Priority Data
63/090,943
13.10.2020
US
63/234,862
19.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 499 | |
| EPO | Filing, Examination | 4906 | |
| Japan | Filing | 504 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 1460 |
Total: 7944 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The disclosure provides for compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 1 diabetes, type 2 diabetes). In some aspects, methods comprise administering first, second, third, fourth, and fifth daily doses of insulin-like growth factor 2 ("IGF-2") or a variant thereof to the subject at respective first, second, third, fourth, and fifth different times, wherein each of the daily doses comprises at least 65 µg of IGF-2. In other aspects, compounds, compositions, and methods containing IGF-2 or variants thereof are used for treating a disorder in a patient in need thereof, such as type 1 or type 2 diabetes.[French]
La présente divulgation concerne des composés, des compositions et leurs méthodes d'utilisation pour le traitement du diabète (p. ex., du diabète de type 1 ou de type 2). Selon certains aspects, les méthodes comprennent l'administration d'une première, d'une deuxième, d'une troisième, d'une quatrième et d'une cinquième doses quotidiennes de facteur de croissance de type insuline 2 (« IGF-2 ») ou d'un variant de celui-ci au sujet à des premier, deuxième, troisième, quatrième et cinquième moments différents, chacune des doses journalières comprenant au moins 65 µg d'IGF-2. Selon d'autres aspects, les composés, les compositions et les méthodes impliquant l'IGF-2 ou des variants de celui-ci sont utilisés pour traiter une affection chez un patient qui en a besoin, p. ex., le diabète de type 1 ou de type 2.